SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-24-026107
Filing Date
2024-08-12
Accepted
2024-08-12 17:15:45
Documents
14
Period of Report
2024-08-06
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20240812_8k.htm   iXBRL 8-K 31519
  Complete submission text file 0001437749-24-026107.txt   185948

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nxrp-20240806.xsd EX-101.SCH 3911
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nxrp-20240806_def.xml EX-101.DEF 13856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nxrp-20240806_lab.xml EX-101.LAB 18278
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nxrp-20240806_pre.xml EX-101.PRE 13888
16 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20240812_8k_htm.xml XML 4970
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241197928
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)